% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Lund:301747,
author = {S. Lund and C. Gong and X. Yu and L. M. Staudt and D. J.
Hodson and S. Scheich$^*$},
title = {{S}trategies for {CRISPR}-based knock-ins in primary human
{B} cells and lymphoma cell lines.},
journal = {Frontiers in immunology},
volume = {16},
issn = {1664-3224},
address = {Lausanne},
publisher = {Frontiers Media},
reportid = {DKFZ-2025-01131},
pages = {1589729},
year = {2025},
abstract = {Since its advent about ten years ago, the CRISPR-Cas9
system has been frequently used in biomedical applications.
It has advanced various fields, and CRISPR-Cas9-based
therapeutics have shown promising results in the treatment
of specific hematological diseases. Furthermore, CRISPR gene
editing technologies have revolutionized cancer research by
enabling a broad range of genetic perturbations, including
genetic knockouts and precise single nucleotide changes.
This perspective focuses on the state-of-the-art methodology
of CRISPR knock-ins to engineer immune cells. Since this
technique relies on homology-directed repair (HDR) of
double-strand breaks (DSBs) induced by the Cas9 enzyme, it
can be used to introduce specific mutations into the target
genome. Therefore, this methodology offers a valuable
opportunity to functionally study specific mutations and to
uncover their impacts not only on overall cell functions but
also on the mechanisms behind cancer-related alterations in
common signaling pathways. This article highlights CRISPR
knock-in strategies, protocols, and applications in cancer
and immune research, with a focus on diffuse large B cell
lymphoma.},
subtyp = {Review Article},
keywords = {Humans / CRISPR-Cas Systems / Gene Knock-In Techniques:
methods / Gene Editing: methods / B-Lymphocytes: metabolism
/ B-Lymphocytes: immunology / Cell Line, Tumor / Lymphoma,
Large B-Cell, Diffuse: genetics / DLBCL (Other) / NF-kappa B
(NF-KB) (Other) / gene editing (CRISPR/Cas9) (Other) /
knock-in (Other) / lymphoma (Other)},
cin = {FM01},
ddc = {610},
cid = {I:(DE-He78)FM01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40453079},
pmc = {pmc:PMC12122508},
doi = {10.3389/fimmu.2025.1589729},
url = {https://inrepo02.dkfz.de/record/301747},
}